How do you put a positive spin on ugly data? AC Immune gives it a shot in the wake of the latest crenezumab flop
Researchers spent close to a decade looking for signs that the failed Alzheimer’s drug crenezumab might work in a study that restricted itself to a group of families with a rare genetic mutation that left them susceptible to early-onset disease.
It failed. And today we’re getting a better look at just how bad the data are — and a biotech’s willingness to tout it anyway as AC Immune takes its turn at the Alzheimer’s Association International Conference.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.